Fremanezumab

FDA APPROVAL DATE: 09/14/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known


There are no adequate data on the developmental risk associated with the use of fremanexumab in pregnant women. The long half life of fremanezumab should be a consideration for women who are pregnant or plan to become pregnant while using fremanezumab.

Contraindicated in patients with serious hypersensitivity to fremanezumab or to any of the excipients.

Our database has 6 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
LOCAL.
RESPIRATORY.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fremanezumab in the Taylor & Francis journal Expert Opinion on Drug Safety. 

(Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 04/18/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top